Amgen's PCSK9 outcomes trial to deliver data sooner than expected

The wait for outcomes data on Amgen's ($AMGN) PCSK9 drug Repatha just got shorter. As CardioBrief reports, top-line results of a study called Fourier will be available in the second half of 2016. If it's positive, expect broader use of the pricey PCSK9 class, which also includes Sanofi ($SNY) and Regeneron's ($REGN) Praluent. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.